/Bio-Techne%20Corp%20site%20magnified%20-by%20Pavel%20Kapysh%20via%20Shutterstock.jpg)
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market cap of $9.6 billion, Bio-Techne operates through Protein Sciences & Diagnostics and Genomics segments.
The biotech major has significantly underperformed the broader market over the past year. Bio-Techne stock prices declined 15.7% in 2025 and plunged nearly 20% over the past year, compared to the S&P 500 Index’s ($SPX) 14.6% gains in 2025 and 12.6% returns over the past year.